Middle East and Africa Asthma Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Middle East and Africa Asthma Market Overview

Asthma continues to require sustained healthcare attention across the Middle East and Africa, where dust exposure, air quality, allergens, and climatic conditions can influence respiratory symptoms. Effective disease management relies on accurate diagnosis, suitable medication, patient education, and continuity of care. The market varies considerably by country because of differences in healthcare infrastructure, insurance coverage, specialist availability, and medicine affordability. Inhaled treatments remain central to routine asthma management, while access to advanced therapies is more variable. The market is poised to reach USD 6.94 Billion by 2035. Improvements in respiratory health awareness, healthcare investment, and diagnostic capabilities may support market development, although disparities in treatment access remain a key challenge.

Middle East and Africa Asthma Market Growth Analysis and Key Influencers

Middle East and Africa Asthma Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Middle East and Africa Asthma Market Growth Drivers

Rising Awareness and Improved Access to Asthma Treatment to Support Market Expansion

Increasing awareness of respiratory diseases and the need for timely asthma management are strengthening demand for accessible medications across the Middle East and Africa. Limited treatment access and misinformation remain significant challenges, creating opportunities for initiatives that improve patient education and medication availability. For instance, in May 2026, The Guardian reported the launch of the Ojumitunrayo Onaara Olufade Foundation in Lagos, Nigeria, to promote respiratory health awareness, provide medications, and support vulnerable patients. Such initiatives are expected to improve treatment access and support market expansion.

Middle East and Africa Asthma Market Restraints

High Asthma Medication Costs to Restrict Market Accessibility

High medication costs and limited affordability restrict access to essential asthma treatments, particularly among low-income populations. These challenges can discourage consistent medication use and encourage patients to adopt unproven alternatives, affecting disease management and treatment demand. For instance, in May 2024, asthma medication prices in Nigeria had increased by more than 500% in less than a year, forcing some patients to reduce medication purchases or seek untested alternatives. Such affordability barriers are likely to constrain market growth.

Middle East and Africa Asthma Market Opportunities

Advancements in Affordable Inhalation Devices to Strengthen Market Potential

The development of affordable and effective inhalation devices presents considerable potential for improving asthma management across the region. Locally developed devices can enhance medication delivery while reducing treatment costs, particularly for children and underserved patients. For instance, in May 2023, the Allergy Foundation of South Africa launched the AfriSpacer, a locally developed, lower-cost spacer designed to improve the delivery of medication from asthma inhalers. Such innovations can expand access to effective respiratory care and create additional growth potential.

Middle East and Africa Asthma Market Trends

The market is witnessing several trends, including collaborative awareness initiatives and improved access to affordable inhalation devices.

Growing Adoption of Collaborative Asthma Awareness Initiatives to Enhance Market Growth

The market is witnessing increasing collaboration between healthcare providers and non-healthcare organizations to improve asthma awareness and access to essential medications. These partnerships support patient education, community outreach, and treatment of accessibility, particularly among underserved populations. For instance, in March 2024, Nemsia Films partnered with Evercare Hospital Lekki in Nigeria to raise asthma awareness and distribute 100 complimentary inhalers to underprivileged patients. Such collaborative initiatives are expected to strengthen treatment awareness and support market growth.

Middle East and Africa Asthma Market Share

Mild Persistent Asthma Segment to Account for a Significant Market Share by Disease Severity

The market is categorized by disease severity into intermittent, mild persistent, moderate persistent, and severe persistent asthma. Among these, mild persistent asthma is expected to account for a significant market share, supported by the need for early diagnosis and consistent disease management. Increasing awareness of respiratory symptoms and the importance of timely treatment can encourage patients with mild but recurring symptoms to seek medical attention. The need for appropriate inhalation therapies and regular symptom control is expected to support demand in this segment.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Middle East and Africa Asthma Market Analysis by Region

The regions included in the report are Saudi Arabia, the United Arab Emirates, Nigeria, South Africa, and others. Among these, South Africa is expected to lead the market, supported by its considerable asthma burden and high prevalence among children. According to Yes2 Breath, asthma is the most common chronic illness among South African children, with approximately half experiencing severe, uncontrolled symptoms. South Africa also ranks 25th worldwide in asthma prevalence and fifth in asthma-related deaths, supporting its significant market potential.

Leading Players in the Middle East and Africa Asthma Market

Middle East and Africa Asthma Market Segmentation

Key Questions Answered in the Middle East and Africa Asthma Market Report

• What was the Middle East and Africa asthma market value in 2025?
• What is the Middle East and Africa asthma market forecast outlook for 2026-2035?
• What are the major factors aiding the Middle East and Africa asthma market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major asthma market trends?
• Which diseases severity is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which age group is likely to dominate the market segment?
• Which distribution channel is anticipated to lead the market segment?
• Who are the key players involved in the Middle East and Africa asthma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with pulmonologists, allergists, respiratory care specialists, hospital procurement managers, and healthcare distributors across the Middle East and Africa to assess treatment patterns, prescribing practices, medication accessibility, and market dynamics.
• Secondary Research: Peer-reviewed publications, asthma epidemiological studies, WHO reports, clinical trial data, and regulatory information. Additional insights are derived from company websites, including Teva Pharmaceutical Industries, GSK, Sanofi, AstraZeneca, and Cipla, covering product portfolios, respiratory therapies, and strategic developments.
• Validation: Market estimates are triangulated using top-down and bottom-up approaches, incorporating country-level analysis across Saudi Arabia, the UAE, Nigeria, and South Africa, with expert feedback to validate market assumptions and forecasts.